UCB (company)




Biopharmaceutical company






















































UCB S.A.
Type
 Société anonyme
Traded as
Euronext: UCB
Industry Pharmaceuticals
Founded 1928
Headquarters
Brussels, Belgium
Key people
 Gerhard Mayr (Chairman), Jean Christophe Tellier (CEO)
Products Biopharmaceuticals
Revenue € 4.632 billion (2018)[1]
Operating income
 € 1.109 billion (2018)[1]
Net income
 € 4.412 billion (2018)[1]
Number of employees
 7,489 (end 2018)[1]
Website www.ucb.com

UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with a revenue of €4.178 billion in 2016[2] which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's, and Crohn's diseases.[3] The Company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders (including epilepsy), inflammatory disorders (including allergy), and oncology.


Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee.




Contents






  • 1 History


  • 2 Notable drugs developed by UCB


  • 3 Corporate governance


  • 4 Operations


  • 5 Scandals


  • 6 References


  • 7 External links





History


UCB was founded on 18 January 1928 by Emmanuel Janssen, a Belgian businessman. Initially focused on industrial chemicals (it was one of the first companies to distill ammonia from coal), the company also included a small pharmaceutical division based around Meurice Laboratories.


In the early 1950s, UCB set up a research centre where new medicines such as Atarax (hydroxyzine) were developed. Successful sales enabled the pharmaceutical division to expand, and led to the discovery of another important compound, called piracetam. This was marketed in the 1970s as Nootropil and used to treat memory and balance problems. It remains one of UCB's key products. At this time, UCB was a company focusing on three core areas: pharmaceuticals, chemicals and films.


The success of Nootropil made it possible for UCB to build a modern pharmaceutical site in Braine-l'Alleud, south of Brussels. There, UCB developed Zyrtec (cetirizine), a blockbuster antihistamine. Other important products have followed including Keppra (levetiracetam), Xyzal (levocetirizine), and Cimzia (certolizumab pegol), which was acquired through the acquisition of Celltech.


At the end of 2002, the chemicals and films divisions were merged and UCB added the resins, additives and adhesives activities of Solutia, to form the surface specialties division. The films part has since been sold to Innovia Films in September 2004. The chemicals division, Methylamines and Derivatives was spun off and later sold to form the company Taminco.


In May 2004, UCB acquired the British biotechnology company Celltech, followed in March 2005 by the sale of the surface specialties to Cytec Industries. By divesting all of its non-pharmaceutical activities, and acquiring Celltech for a mere $1 billion, UCB transformed itself into a global biopharmaceutical company.[4]


In 2006, UCB started the purchase of the German pharmaceutical company Schwarz for 4 billion.[5] As of July 2007[update], UCB holds approximately 87% of Schwarz's outstanding shares. The purchase of Schwarz enabled UCB to introduce two new drugs against CNS disorders: Neupro (rotigotine), a transdermal patch for treatment of Parkinson's disease and Vimpat (lacosamide), a new anticonvulsant. Another new drug of the Schwarz portfolio, Toviaz (fesoterodine), a compound to treat overactive bladder, was licensed to Pfizer in 2006.


In 2008, UCB established a multi-year collaboration with Beryllium, a developer of treatments for immune and CNS disorders.[6] By 2014, this collaboration had yielded "significant scientific breakthroughs", which led to UCB acquiring a minority stake in the company.[6]


In November 2014, UCB announced its intention to sell of its generics subsidiary (Kremers Urban Pharmaceuticals) for more than $1.5 billion to two private equity firms.[7]


In 2015, UCB announced the sale of its branded generics business in India and South Asia to Dr. Reddy's Laboratories for INR 8 billion ($128.38 million).[8][9] In September of the same year the company off loaded its generics business to Lannett for $1.23 billion.[10]



Notable drugs developed by UCB



  • Atarax (hydroxyzine)

  • Briviact (Brivaracetam)

  • Nootropil (piracetam)

  • Zyrtec (cetirizine), an OTC antihistamine

  • Keppra (levetiracetam), an anticonvulsant medication used to treat epilepsy

  • Xyzal (levocetirizine), a third-generation non-sedative antihistamine

  • Cimzia (certolizumab pegol), a monoclonal antibody to TNF-α for the treatment of Crohn's disease and rheumatoid arthritis

  • Neupro (rotigotine), a transdermal patch for treatment of Parkinson's disease

  • Vimpat (lacosamide), an anticonvulsant

  • Atamet (carbidopa/levodopa) for Parkinson's disease



Corporate governance


Jean-Christophe Tellier became the CEO of UCB in January 2015. He is succeeding Roch Doliveux who was the CEO from 2004 until December 2014.[11]



Operations


UCB has operations in over 40 countries and employs more than 7500 people.[12] The United States specialty generics subsidiary was Kremers Urban Pharmaceuticals, established in 1904 and based in Princeton, New Jersey.[13] By November 2015, Lannett Company had acquired Kremers for US$1,230,000,000.[14]



Scandals


In 2004, UCB was fined €10.4 million by the EU for its involvement in a Vitamin B4 price fixing cartel.[15][16] In 2011, UCB was fined $34 million in the US for fraud arising from the mispromotion of Keppra for migraines, despite company research showing it was ineffective for this purpose.[17] In 2015, UCB was investigated by Chinese authorities for corruption and bribery.[18]



References





  1. ^ abcd https://reports.ucb.com/2018/integrated-report/servicepages/downloads/files/entire_en_ucb_ir18.pdf


  2. ^ http://www.ucb.com/investors/Financials/Key-figures


  3. ^ http://www.ucb.com/investors/Financials


  4. ^ Heather Timmons (May 19, 2004). "Belgian drugmaker seeks to buy Celltec". The New York Times..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"""""""'""'"}.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  5. ^ UCB S.A. Press Release of 25 September 2006; accessed on 12 September 2008.


  6. ^ ab Staff (15 June 2014). "UCB Gains Noncontrolling Interest in Beryllium". News Industry Watch. Genetic Engineering & Biotechnology News (Paper). p. 8.


  7. ^ http://www.genengnews.com/gen-news-highlights/ucb-sells-generics-subsidiary-for-1-525b/81250569/


  8. ^ http://www.livemint.com/Companies/zSLHr18TAt5M1ucXLaKiAN/Dr-Reddys-to-buy-select-brands-from-UCB-for-Rs800-crore.html


  9. ^ http://in.reuters.com/article/2015/04/01/ucb-sa-dr-reddys-deals-idINKBN0MS3HK20150401


  10. ^ http://www.fiercepharma.com/story/ucb-hands-us-generics-business-lannett-123b/2015-09-03


  11. ^ "UCB Names EVP Tellier as Successor to CEO Doliveux". GEN News Highlights. Genetic Engineering & Biotechnology News. February 20, 2014.


  12. ^ http://www.ucb.com/our-company/facts/company


  13. ^ "Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion" (Press release). Lannett. 2 September 2015.


  14. ^ House, Douglas W. (27 November 2015). "Lannett completes $1.23B takeover of Kremers Urban Pharma". Seeking Alpha. Retrieved 29 November 2015.


  15. ^ Meller, Paul (2004-12-08). "Europe Is Expected to Fine Members of Vitamin Cartel". The New York Times. ISSN 0362-4331. Retrieved 2015-11-24.


  16. ^ "EC fines BASF, Akzo and UCB Euro66m in choline chloride cartel crackdown". icis.com. 2004-12-09. Retrieved 2015-11-24.


  17. ^ "UCB Pays $34 Million and Pleads Guilty in Epilepsy Drug Fraud Case". Prescriptions Blog. 2011-11-06. Retrieved 2015-11-24.


  18. ^ "China: Belgian Drugmaker UCB Targeted in Wake of GSK Bribery Scandal". International Business Times UK. Retrieved 2015-11-24.
    [date missing]




External links



  • Official website

  • Presscentre.com









Comments

Post a Comment

Popular posts from this blog

Information security

Image
This article is part of a series on Information security Related security categories Internet security Cyberwarfare Computer security Mobile security Network security Threats Computer crime Vulnerability Eavesdropping Malware Spyware Ransomware Trojans Viruses Worms Rootkits Bootkits Keyloggers Screen scrapers Exploits Backdoors Logic bombs Payloads Denial of service Defenses Computer access control Application security Antivirus software Secure coding Secure by default Secure by design Secure operating systems Authentication Multi-factor authentication Authorization Data-centric security Encryption Firewall Intrusion detection system Mobile secure gateway Runtime application self-protection (RASP) v t e Information security , sometimes shortened to InfoSec , is the practice of preventing unauthorized access, use, disclosure, disruption, modification, inspection, recording or destruction of information. Th...
Read more

Lambak Kiri

Image
For Lambak Kiri public housing area, see Lambak Kiri Landless Indigenous Citizens' Housing Scheme. Village in Brunei-Muara, Brunei Lambak Kiri Village Location in Brunei Coordinates: 4°59′26″N 114°57′04″E  /  4.990472°N 114.951114°E  / 4.990472; 114.951114 Coordinates: 4°59′26″N 114°57′04″E  /  4.990472°N 114.951114°E  / 4.990472; 114.951114 Country Brunei District Brunei-Muara Mukim Berakas A Government  • Village head Hamdani Omar Postcode BB1214 Lambak Kiri is a populated place in Brunei-Muara District, Brunei. It is officially a village subdivision under Berakas A, a mukim in the district. Lambak Kiri may also refer to the greater area which includes the Lambak Kiri public housing area of the Landless Indigenous Citizens' Housing Scheme (Malay: Skim Tanah Kurnia Rakyat Jati ), although the latter is a separate subdivision. Contents 1 Name 2 Administration 3 See also 4 References Name ...
Read more

章鱼与海女图

Image
本条目 可参照英語維基百科相應條目来扩充 。 （2014/5/25） 若您熟悉来源语言和主题，请协助参考外语维基扩充条目。请勿直接提交机械翻译，也不要翻译不可靠、低品质内容。依版权协议，译文需在编辑摘要注明来源，或于讨论页顶部标记 {{Translated page}} 标签。 本条目 需要擴充。 （2013年8月15日） 请協助改善这篇條目，更進一步的信息可能會在討論頁或扩充请求中找到。请在擴充條目後將此模板移除。 《 章鱼与海女 》（日语： 蛸と海女 ／ たことあま   Tako to ama ）是一幅由日本畫家葛饰北斋创作的浮世绘，出自1814年（文化4年）出版的艳本《喜能会之故真通》（日语： 喜能会之故真通 ／ きのえのこまつ   Kinoe no Komatsu ）。畫中有兩隻章鱼以觸手攻擊一名採珠的海女，並進行擬似戀獸癖的交媾行為。作品尺寸为6½" × 8¾" （16.51 cm × 22.23 cm）。 [1] 在此之前的类似作品还有北尾重政的艳本《謡曲色番組》及勝川春潮的艳本《艳本千夜多女志》等，有被北斋作为参考的可能性。 《章鱼与海女图》有不同英文翻译，一般称The Dream of the Fisherman's Wife，又作Girl Diver and Octopi、Diver and Two Octopi，Richard Douglas Lane称其为 Girl Diver and Octopi [2] ，Mathi Forrer 称其为 Pearl Diver and Two Octopi [3] ，Danielle Talerico 称其为 Diver and Two Octopi 。 [4] 目录 1 作品介绍 1.1 画中对话 1.2 解释 2 评价 3 影响 3.1 模仿作品 4 另见 5 参考来源 6 外部連結 作品介绍 画中对话 原文 译文 大蛸： いつぞハいつぞハとねらいすましてゐたかいがあつて、けふといふけふ、とうとうとらまへたア。てもむつくりとしたいいぼぼだ。いもよりハなをこうぶつだ。サアサア、すつてすつてすいつくして...
Read more